港股异动 | 科伦博泰生物-B(06990)涨近5% 公司核心产品SKB264于ESMO上中选两项口头报告

智通财经
Oct 31, 2025

智通财经APP获悉,科伦博泰生物-B(06990)涨近5%,截至发稿,涨3.42%,报436港元,成交额8867.3万港元。

消息面上,近日,科伦博泰生物-B发布公告,本公司已在于10月17日至21日在德国柏林举行的2025年欧洲肿瘤内科学会(ESMO)大会上公布多项临床研究成果。

中信建投指出,公司核心产品SKB264于ESMO上中选两项口头报告,其中单药在EGFRm NSCLC的2L+治疗中展现BIC潜力,同时安全性良好,适应症已于10月获批上市;单药用于HR+/HER2- BC的2L+治疗效果明显优于化疗,预计有望于2026年获批。公布核心产品A166一项临床数据,单药用于HER2+ BC的2L+治疗结果超越T-DM1,该适应症已于10月获批上市。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10